TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03757858
Drug: Anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
Study: NCT03409588
Drug: Adempas
Normalized name: Adempas
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
Study: NCT00126438
Drug: 123I-mIBG (meta-iodobenzylguanidine)
Normalized name: mIBG
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose
Study: NCT04786158
Drug: Apomorphine
Normalized name: Apomorphine
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reporting the effects of subcutaneous apomorphine on pain and on quality of life
Study: NCT00941330
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg daily by mouth for 6 to 12 months.
Study: NCT00941330
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Study: NCT00941330
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Study: NCT00818753
Drug: dabigatran 110 mg
Normalized name: dabigatran 110 mg oral capsule
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dabigatran dosages with unfractionated heparin
Study: NCT00818753
Drug: dabigatran 150 mg
Normalized name: dabigatran 150 mg oral capsule
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dabigatran dosages with unfractionated heparin
Study: NCT00818753
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of different dosages dabigatran with unfractionated heparin
Study: NCT00668317
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg BD tablet 8 weeks duration
Study: NCT00668317
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg od nocte tablet 8weeks duration
Study: NCT02952469
Drug: (68Ga)PSMA-HBED-CC
Normalized name: (68Ga)Psma-hbed-CC
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental radiotracer for imaging prostate cancer
Study: NCT00283478
Drug: Iscar Quercus
Normalized name: Quercus muehlenbergii pollen
DrugBank: Quercus muehlenbergii pollen (DB10886)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00283478
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00808951
Drug: Artesunate-amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
Study: NCT02412917
Drug: FV-100
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
DrugBank: Horseradish (DB10674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiviral nucleoside analog
Study: NCT02412917
Drug: valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiviral nucleoside analog
Study: NCT04640870
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
Study: NCT04486391
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg administered via intravenous (IV) infusion once every 3 weeks
Study: NCT04486391
Drug: Salvage Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
Study: NCT01674218
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study: NCT01674218
Drug: PA-824
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study: NCT01356875
Drug: BSC
Normalized name: NHPBSC
DrugBank: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (DB15867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
Study: NCT04562129
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
Study: NCT04562129
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
Study: NCT04562129
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
Study: NCT00202930
Drug: anti-CD20 (Rituximab)
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
Study: NCT03956680
Drug: BMS-986301
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT00022113
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01352962
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000mg/m2 IVPB over 30 min x 1
Study: NCT01352962
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5\*\* IVPB over 30 min x 1
Study: NCT01352962
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
Study: NCT03177291
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation.
Study: NCT03177291
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study: NCT03177291
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study: NCT03177291
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study: NCT01084863
Drug: CT-P6
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P6: administered every 3 weeks
Study: NCT01084863
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin: administered every 3 weeks
Study: NCT01084863
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: administered every 3 weeks
Study: NCT02616666
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
Study: NCT01093092
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01093092
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00545545
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion 125 mg/m2 i.v. over 1.5 hours on Days 1, 8, 15, and 22 of each 6-week treatment cycle
Study: NCT02110784
Drug: Eurartesim tablets
DrugBank: Artenimol (DB11638)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
Study: NCT01998841
Drug: Crenezumab
Normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenezumab will be administered as per the schedule specified in the treatment arm.
Study: NCT03200717
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
Study: NCT02586155
Drug: Apabetalone
Normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule
Study: NCT02586155
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-Intensity Statin
Study: NCT00367978
Drug: Amlodipine/benazepril
Normalized name: AMLODIPINE/BENAZEPRIL
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00141778
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally, once a day
Study: NCT00082277
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/Day Oral
Study: NCT00082277
Drug: Risedronate Sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35mg/week, oral
Study: NCT01406574
Drug: OPB-31121
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
Study: NCT01406574
Drug: OPB-31121 phase2
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
Study: NCT02225431
Drug: sodium chloride infusion
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02258763
Drug: Amoxicillin-Potassium Clavulanate Combination
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antibiotic for 10 days
Study: NCT03682172
Drug: GLP-2 (1pmol/kg/min)
Normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
Study: NCT03682172
Drug: GLP-2 (10pmol/kg/min)
Normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
Study: NCT00902044
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes
Study: NCT00004073
Drug: suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02898610
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04478279
Drug: ST101
Normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
Study: NCT04478279
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide
Study: NCT03871036
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See experimental arm description for more details.
Study: NCT03871036
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: See experimental arm description for more details.
Study: NCT03871036
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: See experimental arm description for more details.
Study: NCT03789656
Drug: Paltusotine
Normalized name: Paltusotine
DrugBank: Paltusotine (DB16277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paltusotine, capsules, once daily by mouth
Study: NCT04158141
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously
Study: NCT04158141
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously
Study: NCT04158141
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenously
Study: NCT04158141
Drug: Pemetrexed Disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenously
Study: NCT03358563
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
Study: NCT03358563
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
Study: NCT03358563
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
Study: NCT01746849
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01746849
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04457284
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +
Study: NCT04457284
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
Study: NCT04457284
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg Q4W IV infusion Cycle 1 +
Study: NCT02415621
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg by mouth (PO) every day (QD)
Study: NCT01724138
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
Study: NCT02420002
Drug: Use of MEOPA during suturing
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
Study: NCT00248729
Drug: Etomidate (20mg) or Midazolam (7mg)
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02970500
Drug: Methylphenidate HCl 10Mg SR
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
Study: NCT00931372
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for subcutaneous injection 100 µg/mL
Study: NCT00379613
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered
Study: NCT00642512
Drug: dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 - 20 mg
Study: NCT00642512
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 - 16 mg
Study: NCT00642512
Drug: dronabinol/ondansetron
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 - 20 mg/8 - 16 mg
Study: NCT03889743
Drug: Dexamethasone treatment during 3 days
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
Study: NCT00169169
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02210364
Drug: lurbinectedin (PM01183)
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lurbinectedin (PM01183) 1 mg and 4 mg vials
Study: NCT01659931
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Tablet
Study: NCT01659931
Drug: Singulair
Normalized name: Singulair
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Tablet
Study: NCT00211679
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT04546581
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir will be given to participants in both groups as standard of care (SOC).
Study: NCT02883114
Drug: PF-06648671
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
Study: NCT02883114
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
Study: NCT03302338
Drug: SAFE group
Normalized name: Safe-Guard
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
Study: NCT00193050
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine